Roivant Sciences $400 million at-the-market offering
We advised the company on an SEC-registered at-the-market offering
Davis Polk advised Roivant Sciences Ltd. in connection with an SEC-registered at-the-market offering program under which Roivant may issue and sell its common shares through the manager, for up to an aggregate offering price of $400 million.
Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch “Vants” – nimble and focused biopharmaceutical and health technology companies.
The Davis Polk corporate team included partner Derek Dostal, counsel Stephen A. Byeff and associates Soo Kyung Chae and Kamil Turkmani. Partner David R. Bauer provided intellectual property advice and counsel Sarah E. Kim and Matthew R. Silver provided 1940 Act advice. Partners Po Sit, Jonathan Cooklin and Kara L. Mungovan provided tax advice. Members of the Davis Polk team are based in the New York and London offices.